We are a global leader in exploiting a novel class of untapped tumour-specific antigens (TSAs), CryptigenTM TSAs, designed to treat a broad patient population.
Epitopea is a transatlantic cancer immunotherapeutics company based in Montreal, Canada and Cambridge, UK.
Our technology platform builds on our proprietary and innovative approach to identifying shared, aberrantly expressed tumour-specific antigens (aeTSA), known as CryptigenTM TSAs, which we have exclusively licensed from the Université de Montréal (UdeM), along with the rights to exploit large sets of CryptigenTM TSAs in solid and hematological cancers.
